Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice

mAbs

Volumn 2, Issue 5, 2010, Pages 571-575

  Vugmeyster, Yulia ^a   DeFranco, David ^a   Pittman, Debra D ^a   Xu, Xin ^a  

^a PFIZER INC   (United States)

Author keywords

ADME; Advanced glycation end products; Autoimmunity; Monoclonal antibody; Pharmacokinetics; RAGE; Sepsis; Tissue distribution

Indexed keywords

RECEPTOR FOR THE ADVANCED GLYCATION END PRODUCT ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; LUNG; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOACTIVITY; SINGLE DRUG DOSE; WILD TYPE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LUNG; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; SPLEEN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 77958594248     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.5.13089     Document Type: Article

References (25)

1. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105:816-22.
2. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009; 7:17.
3. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med 2009; 87:235-47.
4. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology 2005; 15:16-28.
5. Mukherjee TK, Mukhopadhyay S, Hoidal JR. Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology. Respir Physiol Neurobiol 2008; 162:210-5.
6. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, Martin E, et al. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008; 12:201.
7. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, et al. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005; 18:1385-96.
8. Katsuoka F, Kawakami Y, Arai T, Imuta H, Fujiwara M, Kanma H, et al. Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. Biochem Biophys Res Commun 1997; 238:512-6.
9. Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006; 19:1437-45.
10. Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, Makita K, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 2004; 9:165-74.
11. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272:17810-4.
12. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997; 272:16498-506.
13. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-55.
14. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000; 11:1656-66.
15. Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E, et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008; 147:79-83.
16. Lutterloh EC, Opal SM, Pittman DD, Keith JC Jr, Tan XY, Clancy BM, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11:122.
17. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-50.
18. Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, et al. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 299:97-110.
19. 125I]-labeled therapeutic proteins: Application in protein drug development beyond oncology. J Pharm Sci 2010; 99:1028-45.
20. Bazin R, Boucher G, Monier G, Chevrier MC, Verrette S, Broly H, et al. Use of hu-IgG-SCID mice to evaluate the in vivo stability of human monoclonal IgG antibodies. J Immunol Methods 1994; 172:209-17.
21. Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 1999; 29:2819-25.
22. Zuckier LS, Georgescu L, Chang CJ, Scharff MD, Morrison SL. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 1994; 73:794-9.
23. Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, Hanano M. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. J Pharm Sci 1988; 77:200-7.
24. Yanai S, Sugiyama Y, Iga T, Fuwa T, Hanano M. Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am J Physiol 1990; 258:593-8.
25. Finlay WJ, Cunningham O, Lambert MA, Darmanin-Sheehan A, Liu X, Fennell BJ, et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J Mol Biol 2009; 388:541-58.